ClinicalTrials.Veeva

Menu

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

M

MTI University

Status

Enrolling

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: Vildagliptin

Study type

Observational

Funder types

Other

Identifiers

NCT05429554
IDEoo281

Details and patient eligibility

About

The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients

Full description

This study aims to investigate the effect of daily oral DPP4 inhibitors and oral metformin on neurodegeneration in type 2 diabetic patients.

This study aims to compare between the cardiovascular protective properties of DPP-4 inhibitors and Metformin in type 2 diabetic patients.

Enrollment

60 estimated patients

Sex

All

Ages

40 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient should be diagnosed with Type 2 diabetes mellitus (T2DM) and guided with HA1c ≥7, age ≥40 years.
  • moderate hypertension.

Exclusion criteria

  • • Diabetic patients who have been currently receiving anti-diabetic agents other than metformin and/or insulin

    • Patients with type 1 DM, active liver disease, recent history of cardiovascular disease (acute coronary syndrome, coronary artery intervention, New York Heart Association Class III/IV heart failure, stroke, transient ischemic neurologic event, or new/worsening symptoms of coronary heart disease or cerebrovascular disease), severe peripheral vascular disease, triglyceride levels ≥ 600 mg/dL, history of HIV infection, pancreatitis, malignancy or clinically important hematologic disorder, and an estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease formula) less than 30 mL/min/1.73 m2.
    • Moreover, patients with dementia, AD, those were in delirium status during evaluation period, patients with psychotic disease (schizoaffective disorder, etc.)
    • Alcohol and substance addiction were not enrolled in the study.
    • Also, patients who have any hypersensitivity to metformin or to DPP4 inhibitors were also excluded.

Trial design

60 participants in 2 patient groups

group 1
Description:
patients will be treated with DPP4 inhibitor + metformin
Treatment:
Drug: Vildagliptin
control
Description:
patients will be treated with metformin without DPP4 inhibitor.

Trial contacts and locations

1

Loading...

Central trial contact

Dalia Zaafar; Toka H Elemary

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems